Journal of Clinical Oncology, Vol 10, 398-405, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte- macrophage colony-stimulating factor

HM Kantarjian, M Talpaz, D Kontoyiannis, J Gutterman, MJ Keating, EH Estey, S O'Brien, MB Rios, M Beran and A Deisseroth
Department of Hematology, MD Anderson Cancer Center, Houston, TX 77030.

PURPOSE: The study was undertaken to improve the results of intensive chemotherapy in chronic myelogenous leukemia (CML) in accelerated (CML- AP) and blastic phases (CML-BP) by the addition of granulocyte- macrophage colony-stimulating factor (GM-CSF) as supportive therapy. PATIENTS AND METHODS: Forty-eight patients were treated with daunorubicin 120 mg/m2 intravenously on day 1, cytarabine (ara-C) 1.5 g/m2/d by continuous infusion over 24 hours for 4 days, and Solu-Medrol (methylprednisolone; The Upjohn Co, Kalamazoo, MI) 100 mg/d for 5 days, followed on day 5 by GM-CSF 125 micrograms/m2/d over 6 hours until recovery of granulocyte count above 2.0 x 10(3)/microliters. Twenty- four patients had CML-BP, and 24 had CML-AP. RESULTS: During remission induction, 45 patients (94%) developed febrile episodes (fever of unknown origin, 23 patients [48%]; documented infections, 22 patients [46%]). The median time to recovery of granulocyte count above 0.5 x 10(3)/microliters was 29 days and to platelet count above 30 x 10(3)/microliters, 28 days. Overall, 14 of 48 patients (29%) achieved a complete hematologic remission (CHR), and seven (15%) reverted to a second chronic phase. CHR was noted in eight of 24 patients with CML-BP (33%), and in six of 24 patients with CML-AP (25%). Cytogenetic responses were observed in 11 patients (23%), but were transient. Sixteen patients developed either fluid retention, hypotension, pleuropericardial effusions, or pericarditis, or a combination of these side effects. These side effects were severe in four patients and are likely to be disease-associated, as a similar regimen of intensive chemotherapy and GM-CSF at the same dose and schedule in acute lymphocytic leukemia was not associated with these side effects. CONCLUSIONS: The results pertinent to remission rates, induction mortality, myelosuppression profile and related complications, and overall survival were not significantly improved compared with previous experience. In summary, the results of intensive chemotherapy in CML- transformed phases remain poor, despite the addition of GM-CSF as a supportive measure.

This article has been cited by other articles:

				M. H. Cohen, J. R. Johnson, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval Clin. Cancer Res., January 1, 2005; 11(1): 12 - 19. [Abstract] [Full Text] [PDF]

				A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, M. L. Slovak, D. Douer, S. R. Dakhil, and F. R. Appelbaum Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase Blood, August 13, 2002; 100(5): 1910 - 1912. [Abstract] [Full Text] [PDF]

				H. M. Kantarjian, S. O'Brien, J. E. Cortes, T. L. Smith, M. B. Rios, J. Shan, Y. Yang, F. J. Giles, D. A. Thomas, S. Faderl, et al. Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate Clin. Cancer Res., July 1, 2002; 8(7): 2167 - 2176. [Abstract] [Full Text] [PDF]

				C. L. Sawyers, A. Hochhaus, E. Feldman, J. M. Goldman, C. B. Miller, O. G. Ottmann, C. A. Schiffer, M. Talpaz, F. Guilhot, M. W. N. Deininger, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood, May 15, 2002; 99(10): 3530 - 3539. [Abstract] [Full Text] [PDF]

				M. H. Cohen, G. Williams, J. R. Johnson, J. Duan, J. Gobburu, A. Rahman, K. Benson, J. Leighton, S. K. Kim, R. Wood, et al. Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia Clin. Cancer Res., May 1, 2002; 8(5): 935 - 942. [Abstract] [Full Text] [PDF]

				M. Talpaz, R. T. Silver, B. J. Druker, J. M. Goldman, C. Gambacorti-Passerini, F. Guilhot, C. A. Schiffer, T. Fischer, M. W. N. Deininger, A. L. Lennard, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood, March 15, 2002; 99(6): 1928 - 1937. [Abstract] [Full Text] [PDF]